Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition-Reference-Cited by-同舟云学术

Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition

Published:2020-05 Issue:5 Volume:70 Page:711-717
ISSN:0277-2116
Container-title:Journal of Pediatric Gastroenterology & Nutrition
language:en
Short-container-title:

Author:

Indolfi Giuseppe,Fischler Björn,Gonzalez-Peralta Regino P.,Ciocca Mirta,Porta Gilda,Neelam Mohan,El-Guindi Mohamed,Kelly Deirdre,Ni Yen-Hsuan,Sibal Anupan,Leung Daniel H.,Chang Mei Hwei

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Pediatrics, Perinatology, and Child Health

Reference19 articles.

1. Global estimate of HCV infection in the pediatric and adolescent population;El-Sayed;J Hepatol,2015

2. Hepatitis C virus infection in children and adolescents;Indolfi;Lancet Gastroenterol Hepatol,2019

3. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection;Balistreri;Hepatology,2017

4. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection;Wirth;Hepatology,2017

5. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA Study;Jonas;Hepatology,2019

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hépatite C chez l'enfant;Perfectionnement en Pédiatrie;2024-05

2. ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource‐limited settings;Journal of Pediatric Gastroenterology and Nutrition;2024-02-18

3. Viral Infections of the Fetus and Newborn;Avery's Diseases of the Newborn;2024

4. The results of real-world practice with glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection genotypes 1 and 3 in adolescents aged 12 to 17 years in the Moscow region;Almanac of Clinical Medicine;2023-10-06

5. Real-world efficacy and safety of glecaprevir/pibrentasvir in Japanese adolescents with chronic hepatitis C: a prospective multicenter study;Journal of Gastroenterology;2023-02-15